PSMA3 and PML

  • Number of citations of the paper that reports this interaction (PMID 21988832)
  • 14
  • Data Source:
  • BioGRID (affinity chromatography technology, two hybrid)

PSMA3

PML

Gene Name proteasome (prosome, macropain) subunit, alpha type, 3 promyelocytic leukemia
Image No pdb structure
Gene Ontology Annotations Cellular Component
Molecular Function
Biological Process
Pathways
Drugs
Diseases
GWAS
Protein-Protein Interactions 114 interactors: APLN ATN1 ATP6V0C AURKB BTN2A2 BTRC C14orf159 C1orf105 C1QTNF9B-AS1 C9orf106 CCDC69 CCL28 CDK6 CDKN1A CRB3 CRYAB CSNK2A1 CST2 CTAGE5 CTBP1-AS2 CYBA DDX5 DMC1 DMRT3 DVL1 EGR1 FAM103A1 FAM171A2 FAM218A FBXL18 FBXO7 FRAT1 GATA2 GATA3 GFI1B GORASP2 HHEX HNRNPA2B1 IKBKG IQCE KIF1A KIRREL2 KIRREL3-AS3 KRAS KRTAP19-5 KRTAP26-1 KRTAP8-1 LASP1 LBP LETM1 LINC00908 LOC149950 LPHN1 MDM2 MUM1 NEU4 NPBWR2 NPPB NUMBL OSR2 PATL1 PLK1 PML POMP PRNP PRR13 PRR3 PRRC2A PSMA1 PSMA2 PSMA4 PSMA6 PSMA7 PSMB10 PSMB4 PSMB5 PSMD1 PTPN23 PWWP2B RAB3IL1 RAD54L2 RBFOX2 RBM42 RERE RFT1 RTP5 RUSC1-AS1 SERF2 SF1 SH3KBP1 SLAIN1 SLC22A23 SLMO1 SNRPB SNRPC SNRPF SPATA8 SRPK2 STUB1 STX11 STX1A STX4 STX6 TBC1D16 TBX6 TCF7L2 TINCR TRIB3 URB1-AS1 VPS37C XRN2 YPEL3 ZNF366 ZNF385C 101 interactors: ADH1B ANKRD2 ARID3A ARNT ATF2 ATXN1 AURKA AXIN1 BANP BCL2 BCL6 CASP8AP2 CCNT1 CDK1 CDK2 CDK6 CHFR CREBBP CSNK2A1 DAXX EGFR EIF4E ELF4 EP300 FOS GATA2 HDAC1 HDAC2 HDAC3 HHEX HIPK2 HTT KAT5 KAT6A MAPK11 MAPK14 MDM2 MED7 MXD1 MYB MYC NCOA2 NCOR1 NCOR2 NFKB1 NR3C1 NR4A1 PAWR PAXIP1 PCBD2 PIAS1 PIAS2 PIN1 PLAGL1 PLSCR1 POLR2E PPARG PSMA3 RARA RB1 RBX1 RELA RNF111 RNF125 RNF4 RPL11 RXRA SENP2 SH3GL1 SIAH2 SIN3A SIRT1 SKI SMAD3 SP1 SP100 SRF STAT3 SUMO1 SUMO2 SUMO3 SUV39H1 SYNE2 TDG TERF2IP TGFBR1 TGFBR2 TGIF1 THRA TOPBP1 TP53 TP63 TP73 TRIM24 TRIM27 TRIM69 UBE2I UBE2U UBE3A ZBTB16 ZFYVE9
Entrez ID 5684 5371
HPRD ID 01463 00023
Ensembl ID ENSG00000100567 ENSG00000140464
Uniprot IDs P25788 P29590
PDB IDs 1BOR
Enriched GO Terms of Interacting Partners?
Tagcloud ?
20s  alpha5  alpha6  alpha7  alphal  apparatus  cations  dephosphorylation  electrophoretic  endonuclease  endoribonuclease  hydrolysates  possession  postranslational  proteasomal  proteasome  proteasomes  proteolysis  psma1  psma5  psma6  ptm  ribonucleoprotein  rnase  scarcely  spectrometric  tryptic  utr  varies 
anthracycline  apl  approaches  appropriately  arsenic  corepressors  curable  cure  deacetylase  effectiveness  explain  explains  incorporation  minority  oncogenes  pathogenetic  plzf  progranulocytic  promoters  ra  rar  recruit  refinement  relapsed  repression  safe  timed  trioxide  vast 
Tagcloud (Difference) ?
20s  alpha5  alpha6  alpha7  alphal  apparatus  cations  dephosphorylation  electrophoretic  endonuclease  endoribonuclease  hydrolysates  possession  postranslational  proteasomal  proteasome  proteasomes  proteolysis  psma1  psma5  psma6  ptm  ribonucleoprotein  rnase  scarcely  spectrometric  tryptic  utr  varies 
anthracycline  apl  approaches  appropriately  arsenic  corepressors  curable  cure  deacetylase  effectiveness  explain  explains  incorporation  minority  oncogenes  pathogenetic  plzf  progranulocytic  promoters  ra  rar  recruit  refinement  relapsed  repression  safe  timed  trioxide  vast 
Tagcloud (Intersection) ?